Simple Summary This article discusses the use of peptide receptor radionuclide therapy
(PRRT) as a key treatment method for advanced, unresectable neuroendocrine tumors. It …

Simple Summary Pancreatic neuroendocrine tumors are tumors with varying degrees of
aggressiveness. The most frequent site of metastasis is the liver. Treatment methods for …

PURPOSE To compare the efficacy and safety of 177Lu-DOTATATE plus radiosensitizing
capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in …

Simple Summary Tumor resistance, both primary and acquired, is leading to increased
complexity in the nonsurgical treatment of patients with advanced panNENs, which would be …

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), though uncommon,
presents a considerable therapeutic challenge with poor long-term outcomes. Currently …

Peptide receptor chemoradionuclide therapy (PRCRT), the addition of radiosensitising
chemotherapy to peptide receptor radionuclide therapy (PRRT), has been used in individual …

Diagnosis of neuroendocrine tumors (NETs) has increased significantly over the past
decade. Successful detection of metastatic diseases has been achieved through …

Abstract Purpose of Review Peptide receptor radionuclide therapy (PRRT) with [177 Lu-
DOTA 0, Tyr 3] octreotate is an effective and safe second-or third-line treatment option for …

Background: Chronic inflammation has been linked to the development and prognosis of
neuroendocrine tumors (NETs). The current study intended to evaluate the role of peripheral …

The utility of β-emitter 177 Lu-DOTATATE in patients of neuroendocrine tumors (NETs) with
widespread skeletal metastases is limited by its relatively modest response rates and a …